Revenue segments as reported by the company.

Water

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

General and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

IDEXX Laboratories

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IDEXX Labs reports robust Q4 performance, eyes international growth

IDEXX Laboratories delivered strong Q4 results with revenue and profit growth, driven by gains in key segments and customer retention.
While facing challenges from inflationary costs and international headwinds, the company aims for continued growth and market differentiation.
Opportunities lie in expanding organic revenue, focusing on international markets, and enhancing customer engagement for future success.

IDEXX reports robust Q1 performance, eyes pet oncology growth

IDEXX Laboratories delivered a strong Q1 performance with revenue and profit growth across segments.
The company's focus on innovation, cloud adoption, and pet oncology diagnostics positions it well for future growth.
Challenges include U.S. clinical vet visit trends and potential market share competition in lab modalities.
Opportunities lie in pet oncology diagnostics, cloud adoption, and international market growth for IDEXX.

IDEXX Laboratories excels in Q2, eyes pet healthcare trends

IDEXX Laboratories demonstrated robust growth in revenues and profitability, driven by strong performance in key segments.
While facing challenges in international markets and margin pressures, the company is poised to capitalize on pet healthcare trends.
Strategic initiatives like product launches and pricing adjustments position IDEXX well for sustained growth and market leadership.

IDEXX Laboratories excels in Q3 earnings amidst capacity challenges

IDEXX Laboratories demonstrated strong financial performance in Q3, driven by revenue growth and operational efficiency.
While facing challenges in clinical visit trends and capacity management, the company's strategic focus on innovation and market expansion positions it well for future growth.
Opportunities lie in addressing capacity constraints, expanding the sales force, and enhancing customer engagement through diagnostics testing.
Overall, IDEXX's commitment to providing integrated solutions and quality services underscores its resilience and potential for sustained success.

IDEXX Labs posts robust Q4 results, eyes growth through innovation

IDEXX Laboratories delivered strong financial performance in Q4 2023 and aims for continued growth in 2024.
The company's focus on innovation, customer feedback, and operational efficiency positions it well for future success.
Challenges include managing expenses, revenue diversification, and maintaining customer value perception.
Opportunities lie in organic revenue growth, margin improvement, and the launch of new diagnostic tests and platforms.

IDEXX Laboratories reports strong Q1 earnings and growth opportunities

IDEXX Laboratories delivered strong financial performance in Q1 2024, driven by solid organic revenue growth and profit gains.
The company remains committed to innovation, customer-centric solutions, and increasing standard of care in Companion Animal Healthcare.
Challenges in clinical visit growth levels and macro impacts on consumer demand are being addressed through operational focus and technology investments.
Opportunities for growth and improvement in software integration and diagnostic utilization dynamics present avenues for future success.

IDEXX Laboratories reports solid Q2 growth amidst sector challenges

IDEXX Laboratories navigated Q2 2024 with solid revenue growth and a focus on innovation and cost management. Despite challenges from sector trends and macroeconomic headwinds, the company remains optimistic about long-term growth prospects. Ongoing launches and a strong balance sheet position IDEXX well for future opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

DENVER--(BUSINESS WIRE)--The American College of Veterinary Internal Medicine (ACVIM) is excited to announce a new endorsement partnership with IDEXX Laboratories, Inc., of complimentary resident-focused educational resources through their SpringBoard program. This partnership ensures access to high-quality content, evaluated and endorsed by ACVIM, that meets the standards of scientific accuracy and professional relevance for our specialists in training. The demand for reliable online education.

ACVIM and IDEXX Partner to Provide Free Educational Offerings for ACVIM Residents

I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits and missed market expectations, leading to lowered revenue growth guidance for FY24. Despite strong recurring revenue growth and high retention rates, ongoing macroeconomic challenges and high-interest rates are expected to impact IDEXX's business growth.

IDEXX Laboratories Q3: Weak End-Market Demand Continues

ASML Hld

Moderna

Regeneron Pharmaceuticals

Super Micro Computer

Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.

Is It Time to Buy October's Worst-Performing Nasdaq Stocks?

Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today.

A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback

Idexx Laboratories reported a strong earnings beat for Q3 2024, but reduced its revenue guidance.

Idexx Sees Q3 Revenue Boost

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Jonathan Block - Stifel Erin Wright - Morgan Stanley Brandon Vasquez - William Blair David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Third Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded.

IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Transcript

WESTBROOK, Maine--(BUSINESS WIRE)--In the 2024 Growth and Financial Performance Outlook section, second paragraph, second sentence should read: At midpoint, projected full year comparable operating profit margin expansion of 30 - 60 basis points includes a ~40 basis point negative growth impact from lapping a customer contract resolution payment in the first quarter of 2023. (instead of: At midpoint, projected full year comparable operating profit margin expansion of 70 - 100 basis points inclu.

CORRECTING and REPLACING IDEXX Laboratories Announces Third Quarter Results

Idexx Laboratories Inc IDXX reported third-quarter adjusted EPS of $2.79, up 12% year-over-year, beating the consensus of $2.68.

Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth

IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments.

IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket

Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Idexx (IDXX) Reports Q3 Earnings: What Key Metrics Have to Say

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.53 per share a year ago.

Idexx Laboratories (IDXX) Q3 Earnings Surpass Estimates

IDEXX Laboratories trimmed its annual revenue forecast for the third time on Thursday, as the animal health diagnostic equipment maker sees fewer visits to veterinary clinics from pet owners.

IDEXX laboratories cuts annual revenue forecast for third time as pet clinic visits slow

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results. Third Quarter Results The Company reports revenues of $976 million for the third quarter of 2024, an increase of 7% as reported and 6% organic, driven by Companion Animal Group ("CAG") growth of 7% as reported and 6% organic, and Water revenue growth of 13% as reported and organic. CAG Diagnostics recurring revenue growth of 7% as repor.

IDEXX Laboratories Announces Third Quarter Results

Evaluate the expected performance of Idexx (IDXX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Seeking Clues to Idexx (IDXX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?

IDEXX Laboratories' third-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.

IDXX Gears Up for Q3 Earnings: What to Expect From the Stock?

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 third quarter results for Thursday, October 31, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2024 Earnings Snapshot through a link on the IDEXX website, www.

IDEXX Laboratories to Release 2024 Third Quarter Financial Results

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?

Why Is Idexx (IDXX) Up 0.9% Since Last Earnings Report?

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Jay Mazelsky, President and Chief Executive Officer, and Brian McKeon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 from 11:30 am – 12:05 pm (EDT). A live audio webcast of the presentation will be available through a.

IDEXX Laboratories to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

IDEXX reported lower full-year organic revenue growth due to reduced U.S. clinical visits. Weak consumer sentiment and ongoing staffing challenges may continue to impact clinical visits in the near future. Launch of new menu expansion for Catalyst platform may drive growth in diagnostic business, but the stock remains overvalued.

IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits

Tuesday, Idexx Laboratories Inc IDXX reported second-quarter adjusted EPS of $3.02, up 15% year-over-year, beating the consensus of $2.88.

Animal Health Firm Idexx's Robust Business Model Bolsters Position Despite Slower Growth, Says Analyst

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants Chris Schott - JPMorgan Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jonathan Block - Stifel David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Second Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded.

IDEXX Laboratories, Inc. (IDXX) Q2 2024 Earnings Call Transcript

IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.

IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down

The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Idexx (IDXX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.44 per share, missing the Zacks Consensus Estimate of $2.87 per share. This compares to earnings of $2.67 per share a year ago.

News for IDEXX Laboratories Stock (IDXX)